1.98

4.81% -0.10

Pulmonx Corp (LUNG)

Overview News Price History Option Chain Financials Discussions Forecast

Pulmonx Corp stock is traded at $1.98, with a volume of 451.85K. It is down -4.81% in the last 24 hours and down -2.94% over the past month. Pulmonx Corp is a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). solution, which is comprised of the Zephyr Endobronchial Valve (Zephyr Valve), the Chartis Pulmonary Assessment System (Chartis System), and the LungTraX Platform, is designed to treat severe emphysema patients who, despite medical management, are still profoundly symptomatic and either do not want or are ineligible for surgical approaches. The majority of the company's revenue is generated from the provision of cloud hosting and management services. The company geographically, operates in the USA, the EMEA, the Asia Pacific, and other international regions, the majority of revenue from USA.

Previous Close:

$2.08

Open:

$2.12

24h Volume:

451.85K

Relative Volume:

0.80

Market Cap:

$85.04M

Revenue:

$88.55M

Net Income/Loss:

$-53.21M

P/E Ratio:

-1.5303

EPS:

-1.2939

Net Cash Flow:

$-29.48M

1W Performance:

-13.16%

1M Performance:

-2.94%

6M Performance:

+8.79%

1Y Performance:

+17.16%

1-Day Range:

$1.98

$2.16

1-Week Range:

$1.98

$2.33

52-Week Range:

$1.13

$2.89

Pulmonx Corp Stock (LUNG) Company Profile

Name

Pulmonx Corp

Sector

Healthcare (1069)

Industry

Medical Devices (139)

Phone

650-364-0400

Address

700 CHESAPEAKE DRIVE, REDWOOD CITY

Employee

296

Twitter

Next Earnings Date

2026-07-29

Latest SEC Filings

LUNG's Discussions on Twitter

Compare LUNG vs ABT, MDT, SYK, BSX, EW

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
LUNG Pulmonx Corp	1.98	89.33M	88.55M	-53.21M	-29.48M	-1.2939
ABT Abbott Laboratories	105.23	182.59B	46.59B	5.41B	7.38B	3.0938
MDT Medtronic Plc	91.89	118.18B	36.36B	4.84B	5.43B	3.7261
SYK Stryker Corp	275.39	106.03B	25.27B	3.34B	4.57B	8.6334
BSX Boston Scientific Corp	44.96	65.19B	20.62B	3.56B	3.48B	2.3847
EW Edwards Lifesciences Corp	86.18	49.99B	6.30B	1.07B	1.09B	1.8406

Pulmonx Corp Stock (LUNG) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jul-31-25	Downgrade	Piper Sandler	Overweight → Neutral
Mar-10-25	Initiated	D. Boral Capital	Buy
Dec-11-24	Downgrade	Citigroup	Buy → Neutral
Jun-04-24	Initiated	Lake Street	Buy
Feb-23-24	Downgrade	Wells Fargo	Overweight → Equal Weight
Sep-05-23	Initiated	Craig Hallum	Buy
Feb-27-23	Upgrade	Wells Fargo	Equal Weight → Overweight
Jan-03-23	Downgrade	BofA Securities	Neutral → Underperform
Dec-12-22	Upgrade	Citigroup	Neutral → Buy
Jul-11-22	Downgrade	Citigroup	Buy → Neutral
Mar-02-22	Resumed	BofA Securities	Neutral
Dec-08-21	Upgrade	Piper Sandler	Neutral → Overweight
Apr-01-21	Initiated	Citigroup	Buy
Mar-25-21	Initiated	Piper Sandler	Neutral
Mar-10-21	Upgrade	BofA Securities	Neutral → Buy
Jan-04-21	Downgrade	BofA Securities	Buy → Neutral
Oct-26-20	Initiated	BofA Securities	Buy
Oct-26-20	Initiated	Canaccord Genuity	Buy
Oct-26-20	Initiated	Morgan Stanley	Equal-Weight
Oct-26-20	Initiated	Stifel	Buy
Oct-26-20	Initiated	Wells Fargo	Equal Weight

View All

Pulmonx Corp Stock (LUNG) Latest News

Sep 04, 2026

Pulmonx Corp Officer Radhakrishnan Srikanth Sells 14,245 Shares at $2.26 Each (NASDAQ: LUNG) - Kalkine Media

Sep 04, 2026

Pulmonx general counsel David Lehman sells $32,393 in stock By Investing.com - Investing.com South Africa

Sep 04, 2026

Pulmonx CEO French Glendon E. III Disposes of 41,882 Shares at $2.26 Each - Kalkine Media

Sep 04, 2026

Pulmonx CCO Geoffrey Rose sells $17,804 in lung shares By Investing.com - Investing.com South Africa

Sep 04, 2026

Pulmonx chief science officer sells $32,192 in stock By Investing.com - Investing.com Australia

Sep 04, 2026

Sep 03, 2026

Pulmonx Corporation Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance

Sep 01, 2026

Aug 27, 2026

Pulmonx will take investor meetings in Boston and New York Sept. 9-10 - Stock Titan

Aug 27, 2026

Pulmonx to Participate in Upcoming Investor Conferences - Yahoo Finance

Aug 27, 2026

Aug 19, 2026

Pulmonx Corp (NASDAQ: LUNG) Share Price, LUNG Stock News, LUNG Share Price & Updates - Kalkine

Aug 19, 2026

Aug 15, 2026

Pulmonx Rebuilds Sales Force, Targets Growth and AeriSeal Launch Next Year - MarketBeat

Aug 15, 2026

Aug 14, 2026

What Makes Pulmonx Corporation (LUNG) a Strong Momentum Stock: Buy Now? - Yahoo Finance

Aug 14, 2026

Aug 13, 2026

Morgan Stanley (LUNG) reports 6.9% Pulmonx stake in updated ownership filing - Stock Titan

Aug 13, 2026

Aug 11, 2026

Pulmonx at Canaccord Genuity growth conference: turnaround gains pace - Investing.com

Aug 11, 2026

Aug 07, 2026

Pulmonx (LUNG) Q2 2026 Earnings Call Transcript - The Globe and Mail

Aug 07, 2026

Aug 04, 2026

Pulmonx Corp 2026: Revenue $22.76M, EPS ($0.24) — 10-Q Summary - TradingView

Aug 04, 2026

Aug 03, 2026

Pulmonx (LUNG) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance

Aug 03, 2026

Aug 01, 2026

Earnings Release: Here's Why Analysts Cut Their Pulmonx Corporation (NASDAQ:LUNG) Price Target To US$3.40 - Sahm

Aug 01, 2026

Jul 30, 2026

LUNG Looks 82.5% Undervalued on GF Value™ Despite Financial Chal - GuruFocus

Jul 30, 2026

Pulmonx Target of Unusually Large Options Trading (NASDAQ:LUNG) - MarketBeat

Jul 30, 2026

Jul 29, 2026

Earnings call transcript: Pulmonx tops Q2 2026 estimates, shares jump 14.4% - Investing.com

Jul 29, 2026

Pulmonx Q2 Revenue Falls 5 Percent To $22.8 Million - Quiver Quantitative

Jul 29, 2026

Jul 28, 2026

Pulmonx's Aug. 11 Boston fireside chat will be webcast live - Stock Titan

Jul 28, 2026

Jul 27, 2026

LUNG|Pulmonx Corp|Price:1.225|Chg%:+0.055 - TradingKey

Jul 27, 2026